This article presents the planned safety analyses for the first 40 patients randomized to radioembolization with yttrium-90 ( ( 90 ) Y ) resin microspheres followed by sorafenib ( n = 20 ) or sorafenib only ( n = 20 ) in the SORAMIC study .